GTCM
VRDN icon

Gyon Technologies Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Gyon Technologies Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,086
Closed -$236K – 411
2022
Q4 		$236K Sell
8,086
-1,813
-18% -$41.8K 0.09% 284
2022
Q3 		$203K Buy
+9,899
New +$178K 0.06% 329
2022
Q2 		– Sell
-12,187
Closed -$225K – 570
2022
Q1 		$225K Buy
+12,187
New +$234K 0.16% 223

Other funds holding VRDN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Gyon Technologies Capital Management's VRDN Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of Viridian Therapeutics (VRDN) in Q1 2023, closing a stake of 8,086 shares — an estimated $236K sold.

Gyon Technologies Capital Management first reported a position in VRDN in Q1 2022 and held it in 3 quarters. The position peaked at $236K in Q4 2022. 135 funds tracked by Wall St. Rank hold VRDN as of Q1 2023.

  • Gyon Technologies Capital Management reported no remaining Viridian Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 8,086 Viridian Therapeutics shares in Q1 2023, an estimated $236K.
  • Gyon Technologies Capital Management first reported a position in Viridian Therapeutics in Q1 2022 and held it in 3 quarters.
  • Gyon Technologies Capital Management's Viridian Therapeutics position peaked at $236K in Q4 2022.
  • 135 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.